Desentum

Desentum is a Finnish biotech innovator developing next-generation allergen immunotherapies using its proprietary recombinant hypoallergen technology. The company's lead candidates aim to significantly reduce treatment duration and the risk of severe adverse reactions by modifying allergens to suppress IgE-mediated histamine release. Having completed a rapid €8 million financing round in 2026, Desentum is advancing its lead program for birch pollen allergy through Phase 2 clinical trials. The company seeks to address major limitations of current AIT, positioning itself in the large and growing global allergy treatment market.

Platform for engineering recombinant hypoallergens through targeted protein modifications to reduce IgE cross-linking and allergenic potential, while retaining native conformation to induce protective immune responses. Includes a controlled-release formulation for subcutaneous injection.

Desentum competes with companies developing next-generation AIT, including those using allergoids (chemically modified extracts), peptide vaccines, and adjuvanted formulations. It also competes with the entrenched market of natural allergen extract products from companies like ALK-Abelló, Stallergenes Greer, and Merck. In peanut allergy, it faces competition from oral immunotherapies (e.g., Palforzia) and other investigational approaches.